Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461889 | 0.82 | GSK3B (0.52) | LATS1GSK3BRAD52ROCK1HTR2C | |
| SCHEMBL38663101 | 0.82 | GSK3B (0.52) | LATS1GSK3BRAD52ROCK1HTR2C | |
| SCHEMBL26669231 | 0.82 | GSK3B (0.52) | LATS1GSK3BRAD52ROCK1HTR2C | |
| Hydrochloric Acid SCHEMBL30619012 | 0.81 | GSK3B (0.51) | LATS1GSK3BRAD52ROCK1HTR2C | |
| SCHEMBL30609670 | 0.80 | CHRNB2 (0.55) | LATS1ROCK1HTR2CHTR2AHTR2B | |
| SCHEMBL5464361 | 0.80 | CHRNB2 (0.55) | LATS1ROCK1HTR2CHTR2AHTR2B | |
| SCHEMBL17884780 | 0.80 | CHRNB2 (0.55) | LATS1ROCK1HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL27544714 | 0.79 | CHRNB2 (0.53) | LATS1ROCK1 | |
| SCHEMBL18291389 | 0.77 | CHRNB2 (0.49) | LATS1GSK3BRAD52CDK4ROCK1 | |
| SCHEMBL20038550 | 0.77 | CHRNB2 (0.49) | LATS1GSK3BRAD52CDK4ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294550-A1 | 8-OXA-3-AZABICYCLO[3.2.1]OCTANE COMPOUNDS OR SALT THEREOF, AND PREPARATION METHOD AND USE THEREOF | LITTDD MEDICINES LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4378943-A1 | 8-OXO-3-AZABICYCLO[3.2.1]OCTANE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Littdd Medicines Ltd (CN) | 2024-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294550-A1 | 8-OXA-3-AZABICYCLO[3.2.1]OCTANE COMPOUNDS OR SALT THEREOF, AND PREPARATION METHOD AND USE THEREOF | ATR, OGG1, ATRIP | LATS1 625/4885GSK3B 273/4885RAD52 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.